Extended anaerobic coverage in aspiration pneumonia not associated with additional mortality benefit: Study
Aspiration pneumonia, a serious condition resulting from the inhalation of oral or gastric contents into the lungs, often requires antibiotic treatment. However, the optimal choice of antibiotics, particularly regarding anaerobic coverage, remains debated.
A recent study aimed to compare outcomes between antibiotic therapy with limited anaerobic coverage (LAC) versus extended anaerobic coverage (EAC) in patients with community-acquired aspiration pneumonia. This study was published in the journal Chest by Anthony D Bai and colleagues. Current guidelines do not recommend extended anaerobic coverage for aspiration pneumonia, yet it is still commonly prescribed.
A multicenter retrospective cohort study across 18 hospitals in Ontario, Canada, analyzed data from 3,999 patients diagnosed with community-acquired aspiration pneumonia between 2015 and 2022. Patients were categorized into LAC or EAC groups based on the antibiotics prescribed within 48 hours of admission. The primary outcome was in-hospital mortality, with Clostridioides difficile colitis incidence as a secondary outcome. Propensity score weighting was used to balance baseline factors between the two groups.
The key findings of the study were:
Of the included patients, 2,683 received LAC and 1,316 received EAC.
In-hospital mortality rates were 30.3% in the LAC group and 32.1% in the EAC group.
Clostridioides difficile colitis occurred in ≤0.2% of the LAC group and 0.8% to 1.1% of the EAC group.
After adjusting for baseline factors, the difference in in-hospital mortality between the EAC and LAC groups was 1.6%, with a 1.0% difference in Clostridioides difficile colitis risk.
The study suggests that extended anaerobic coverage does not provide additional benefits in terms of in-hospital mortality for patients with community-acquired aspiration pneumonia. However, it is associated with an increased risk of Clostridioides difficile colitis. These findings highlight the importance of aligning antibiotic therapy with evidence-based guidelines to optimize patient outcomes and minimize the risk of adverse events.
Reference:
Bai, A. D., Srivastava, S., Digby, G. C., Girard, V., Razak, F., & Verma, A. A. Anaerobic antibiotic coverage in aspiration pneumonia and the associated benefits and harms: A retrospective cohort study. Chest,2024. https://doi.org/10.1016/j.chest.2024.02.025
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.